Cited by 867Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsCell death mechanisms and regulation

The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.

Exploiting senescence for the treatment of cancer

Wang, Liqin, Lankhorst, Lina, Bernards, René·2022·Nature Reviews Cancer

DOI 10.1038/s41568-022-00450-9

Open this paper in CoChat — free account

Abstract

Senescence is a cellular response to a variety of stress signals that is characterized by a stable withdrawal from the cell cycle and major changes in cell morphology and physiology. While most research on senescence has been performed on non-cancer cells, it is evident that cancer cells can also mount a senescence response. In this Review, we discuss how senescence can be induced in cancer cells. We describe the distinctive features of senescent cancer cells and how these changes in cellular physiology might be exploited for the selective eradication of these cells (senolysis). We discuss activation of the host immune system as a particularly attractive way to clear senescent cancer cells. Finally, we consider the challenges and opportunities provided by a 'one-two punch' sequential treatment of cancer with pro-senescence therapy followed by senolytic therapy.

Integrity signals

Registry

Crossref · 10.1038/s41568-022-00450-9

Cites

265 of 265 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–265 of 265

Tumor cell senescence response produces aggressive variants
Yang, L., Fang, J., & Chen, J. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.49 · Cited by 132
Is Senescence-Associated β-Galactosidase a Reliable in vivo Marker of Cellular Senescence During Embryonic Development?
de Mera‐Rodríguez, J. A., Álvarez‐Hernán, G., Gañán, Y., Martín‐Partido, G., Rodríguez‐León, J., & Francisco‐Morcillo, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.623175 · Cited by 132
Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma
Gonzalez-Meljem, J. M., Haston, S., Carreno, G., Apps, J. R., Pozzi, S., Stache, C., Kaushal, G., Virasami, A., Panousopoulos, L., Mousavy-Gharavy, S. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01992-5 · Cited by 130
Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells
Wang, L., Tang, C., Cao, H., Li, K., Pang, X., Zhong, L., Dang, W., Tang, H., Huang, Y., Wei, L., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1056409 · Cited by 129
Self-citation
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Lyman, G. H., Nguyen, A., Snyder, S., Gitlin, M. D., & Chung, K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2072 · Cited by 128
Role of telomeres and telomerase in genomic instability, senescence and cancer
Deng, Y., & Chang, S. S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700673 · Cited by 127
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Cellular Senescence - its role in cancer and the response to ionizing radiation
Sabin, R. J., & Anderson, R. M. (2011) · Genome Integrity · doi:10.1186/2041-9414-2-7 · Cited by 123
p53-Dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions
Gorgoulis, V. G., Pratsinis, H., Zacharatos, P., Demoliou, C., Sigala, F., Asimacopoulos, P. J., Papavassiliou, A. G., & Kletsas, D. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700241 · Cited by 122
MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo
Huck, J. J., Zhang, M., McDonald, A. A., Bowman, D., Hoar, K. M., Stringer, B., Ecsedy, J. A., Manfredi, M. G., & Hyer, M. L. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0300 · Cited by 119
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano‐Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez‐Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 119
Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress
Falchook, G. S., Bastida, C. C., & Kurzrock, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.022 · Cited by 115
Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts
Ryu, S. J., Oh, Y. S., & Park, S. C. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402091 · Cited by 114
Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer
Kovačovicova, K. L., Školnaja, M., Heinmaa, M., Mistrík, M., Pata, P., Pata, I., Bártek, J., & Vinciguerra, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00459 · Cited by 113
A Proteomic Atlas of Senescence-Associated Secretomes for Aging Biomarker Development
(2019) · doi:10.1101/604306 · Cited by 110
Notch3 Functions as a Tumor Suppressor by Controlling Cellular Senescence
Cui, H., Kong, Y., Xu, M., & Zhang, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3902 · Cited by 106
The Microtubule Stabilizing Agent Discodermolide is a Potent Inducer of Accelerated Cell Senescence
Klein, L. E., Freeze, B. S., Smith, A. B., & Horwitz, S. B. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1550 · Cited by 104
C/EBPγ Suppresses Senescence and Inflammatory Gene Expression by Heterodimerizing with C/EBPβ
Huggins, C. J., Malík, R., Lee, S., Salotti, J., Thomas, S., Martín, N. C. R., Quiñones, O. A., Alvord, W. G., Olanich, M. E., Keller, J. R., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01674-12 · Cited by 102
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 102
Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99
Exosomes as Emerging Pro-Tumorigenic Mediators of the Senescence-Associated Secretory Phenotype
Jakhar, R., & Crasta, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102547 · Cited by 98
Send in the senolytics
Dolgin, E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00750-1 · Cited by 95
Cellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Mitri, D. D., & Alimonti, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.005 · Cited by 92
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Kumarasamy, V. M., Vail, P. J., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2275 · Cited by 89
Exploiting tumor cell senescence in anticancer therapy
Lee, M., & Lee, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.2.005 · Cited by 85
Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
Burchett, K. M., Yan, Y., & Ouellette, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085155 · Cited by 84
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Knudsen, E. S., Kumarasamy, V. M., Chung, S., Ruiz, A., Vail, P. J., Tzetzo, S. L., Wu, J., Nambiar, R., Sivinski, J., Chauhan, S. S., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321000 · Cited by 83
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
Cleary, J. M., Lima, C. M. S. R., Hurwitz, H. I., Montero, A. J., Franklin, C., Yang, J., Graham, A., Busman, T., Mabry, M., Holen, K., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0110-9 · Cited by 80
Effects of novel HDAC inhibitors on urothelial carcinoma cells
Kaletsch, A., Pinkerneil, M., Hoffmann, M. J., Vasudevan, A. A. J., Wang, C., Hansen, F. K., Wiek, C., Hanenberg, H., Gertzen, C. G. W., Gohlke, H., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0531-y · Cited by 77
Beta-galactosidase staining on bone marrow. The osteoclast pitfall.
Kopp, H., Hooper, A. T., Shmelkov, S. V., & Rafii, S. (2007) · PubMed · doi:10.14670/hh-22.971 · Cited by 76
Deletion of Rb Accelerates Pancreatic Carcinogenesis by Oncogenic Kras and Impairs Senescence in Premalignant Lesions
Carrière, C., Gore, A. J., Norris, A. M., Gunn, J. R., Young, A. L., Longnecker, D. S., & Korc, M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.041 · Cited by 76
Telomerase as a Cancer Target. Development of New Molecules
Gómez, D. L. M., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160212122425 · Cited by 76
Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines
Driscoll, D. L., Chakravarty, A., Bowman, D., Shinde, V., Lasky, K., Shi, J. Q., Vos, T. J., Stringer, B., Amidon, B., D’Amore, N. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111060 · Cited by 62
Increase therapy-related leukemia secondary to breast cancer
Pm, C., Sgro, C., Parchin-Geneste, N., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401787 · Cited by 61
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
Fung, A. S., Wu, L., & Tannock, I. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3007 · Cited by 59
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Self-citation
Blockbuster dreams for Pfizer's CDK inhibitor
Guha, M. (2013) · Nature Biotechnology · doi:10.1038/nbt0313-187a · Cited by 49
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Klein, M. E., Dickson, M. A., Antonescu, C. R., Qin, L., Dooley, S. J., Barlas, A., Manova, K., Schwartz, G. K., Crago, A. M., Singer, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0332-y · Cited by 49
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation
Wang, L.-X., Wang, J., Chen, J.-J., Long, B., Liu, L.-L., Tu, X.-X., Luo, Y., Hu, Y., Lin, D.-J., Lu, G., et al. (2016) · Scientific Reports · doi:10.1038/srep35533 · Cited by 46
Self-citation
Pyrazolo–pyrimidine‐derived c‐Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling
Donnini, S., Monti, M., Castagnini, C., Solito, R., Botta, M., Schenone, S., Giachetti, A., & Ziche, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22410 · Cited by 45
Senescence and Immunoregulation in the Tumor Microenvironment
Ruhland, M. K., & Alspach, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.754069 · Cited by 45
Gemcitabine induces cell senescence in human pancreatic cancer cell lines
Song, Y. H., Baba, T., & Mukaida, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.063 · Cited by 44
Role of senescence induction in cancer treatment
Qin, S., Schulte, B. A., & Wang, G. Y. (2018) · World Journal of Clinical Oncology · doi:10.5306/wjco.v9.i8.180 · Cited by 44
Prevalent intron retention fine‐tunes gene expression and contributes to cellular senescence
Yao, J., Ding, D., Li, X., Shen, T., Fu, H., Zhong, J., Wei, G., & Ni, T. (2020) · Aging Cell · doi:10.1111/acel.13276 · Cited by 43
A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells
Augello, G., Puleio, R., Emma, M. R., Cusimano, A., Loria, G. R., McCubrey, J. A., Montalto, G., & Cervello, M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1138183 · Cited by 41
Ionizing Radiation Sensitizes Breast Cancer Cells to Bcl-2 Inhibitor, ABT-737, through Regulating Mcl-1
Wu, H., Schiff, D. S., Lin, Y., Neboori, H. J., Goyal, S., Feng, Z., & Haffty, B. G. (2014) · Radiation Research · doi:10.1667/rr13856.1 · Cited by 39
The mTORC1-autophagy pathway is a target for senescent cell elimination
Kucheryavenko, O., Nelson, G., von Zglinicki, T., Korolchuk, V. I., & Carroll, B. (2019) · Biogerontology · doi:10.1007/s10522-019-09802-9 · Cited by 39
Signal Transducer and Activator of Transcription 3 (STAT3) Suppresses STAT1/Interferon Signaling Pathway and Inflammation in Senescent Preadipocytes
Madani, A. Y., Majeed, Y., Abdesselem, H., Agha, M. V., Vakayil, M., Sukhun, N. K. A., Halabi, N. M., Kumar, P., Hayat, S., Elrayess, M. A., et al. (2021) · Antioxidants · doi:10.3390/antiox10020334 · Cited by 37
Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations
Piscitani, L., Sirolli, V., Liberato, L. D., Morroni, M., & Bonomini, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144878 · Cited by 36
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma
Amatori, S., Bagaloni, I., Viti, D., & Fanelli, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.016 · Cited by 34
A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors
Puglisi, M., Molife, L. R., Jonge, M. J. D., Khan, K. H., van Doorn, L., Forster, M. D., Blanco, M., Gutierrez, M. E., Franklin, C. A., Busman, T. A., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0140 · Cited by 33
Downregulation of Polo-Like Kinase 1 Induces Cellular Senescence in Human Primary Cells Through a p53-Dependent Pathway
Kim, H., Cho, J. H., & Kim, J.-R. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt017 · Cited by 30
Epigenetic modulation of gene expression of human leukemia cell lines – induction of cell death and senescence
Elknerová, K., Myslivcová, D., Lacinová, Z., Marinov, I., Uherková, L., & Stöckbauer, P. (2010) · Neoplasma · doi:10.4149/neo_2011_01_35 · Cited by 27
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Liu, Y., Hawkins, O. E., Vilgelm, A. E., Pawlikowski, J. S., Ecsedy, J., Sosman, J. A., Kelley, M. C., & Richmond, A. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0293 · Cited by 26
The role of aurora A and polo-like kinases in high-risk lymphomas
Murga‐Zamalloa, C., Inamdar, K. V., & Wilcox, R. A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000232 · Cited by 24
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
Witzens‐Harig, M., Memmer, M.-L., Dreyling, M. H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-308 · Cited by 22
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
Mayer, E. L., Wander, S. A., Regan, M. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps1104 · Cited by 21
Senolysis Reduces Senescence in Veins and Cancer Cell Migration
Estepa‐Fernández, A., Alfonso, M., Morellá‐Aucejo, Á., García‐Fernández, A., Lérida‐Viso, A., Lozano‐Torres, B., Galiana, I., Soriano‐Teruel, P. M., Sancenón, F., Orzáez, M., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100149 · Cited by 19
The Cancer Senescopedia – Delineation of Cancer Cell SenescencePreprint
Jochems, F., Thijssen, B., Janssen, R. M. E., Conti, G. D., Pogacar, Z., Wang, L., Schepers, A. G., Wang, C., Jin, H., Beijersbergen, R. L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3762763 · Cited by 18
Self-citation
Methotrexate-induced senescence of human colon cancer cells depends on p53 acetylation, but not genomic aberrations
Dąbrowska, M., Skoneczny, M., Uram, Ł. S., & Rode, W. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000731 · Cited by 17
A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
Trivedi, N., Armstrong, S. A., Wang, H., Hartley, M. L., Deeken, J. F., He, A. R., Subramaniam, D. S., Melville, H., Albanese, C., Marshall, J. L., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3672 · Cited by 17
Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers
Das, K., Lorena, P. D. N., Ng, L. K., et al. (2010) · Pathology · doi:10.3109/00313025.2010.508789 · Cited by 16
A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)
Brachet, P.-E., Fabbro, M., Leary, A. F., Médioni, J., Follana, P., Lesoin, A., Frenel, J., Lacourtoisie, S. A., Floquet, A., Gladieff, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx372.044 · Cited by 6
Abstract 1146: [18F]FPyGal: A novel ß-galactosidase specific PET tracer forin vivoimaging of tumor senescence
Krueger, M. A., Cotton, J. M., Zhou, B., et al. (2019) · Tumor Biology · doi:10.1158/1538-7445.sabcs18-1146 · Cited by 4

Research works printed but not linked: 1

Ekpenyong-Akiba, A. E., Poblocka, M. & Macip, S. In Senolytics in Disease, Ageing and Longevity (Springer, 2020).

Sorted by citations

Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Self-citation
Senescent alveolar macrophages promote early-stage lung tumorigenesis
Prieto, L. I., Sturmlechner, I., Graves, S. I., Zhang, C., Goplen, N. P., Yi, E. S., Sun, J., Li, H., & Baker, D. J. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.006 · Cited by 212
Senescence-Associated β-Galactosidase Detection in Pathology
Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022) · Diagnostics · doi:10.3390/diagnostics12102309 · Cited by 182

See all 867

Authors: Wang, L., Lankhorst, L., & Bernards, R.
Affiliations: The Netherlands Cancer Institute (NL)
Utrecht University (NL)
Corresponding author: Bernards, René
ORCID: Wang, Liqin
Lankhorst, Lina
Bernards, René
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2022-03-03
Volume: 22
Issue: 6
Pages: 340-355
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-022-00450-9
OpenAlex: W4221091893
Cited by: 867
References: 265
Citations by year: 2026: 161 · 2025: 237 · 2024: 254 · 2023: 141 · 2022: 73
FWCI: 24.68
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: cellular senescence, senolysis, senolytic therapy
MeSH terms: Cell Cycle, Humans, Neoplasms, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exploiting senescence for the treatment of cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks